頁籤選單縮合
| 題 名 | 表皮生長因子抑制劑皮膚併發症=Skin Toxicities Associated with Epidermal Growth Factor Receptor Inhibitor |
|---|---|
| 作 者 | 林政仁; 吳雀維; 劉親穎; | 書刊名 | 藥學雜誌 |
| 卷 期 | 30:1=118 2014.03[民103.03] |
| 頁 次 | 頁101-105 |
| 分類號 | 418.33 |
| 關鍵詞 | 表皮生長因子接受器抑制劑; 皮膚毒性; Epidermal growth factor receptor inhibitors; Skin toxicities; |
| 語 文 | 中文(Chinese) |
| 中文摘要 | 皮膚毒性是表皮生長因子接受器抑制劑 (epidermal growth factor receptor inhibitors,EGFRIs) 治療時最常見的副作用,根據一些研究文獻指出,其發生率高達60-80%以上。其中又以痤瘡樣皮疹 (acneiform eruption) 或丘疹膿疱皮疹 (papulopustular eruption)、皮膚瘙癢 (pruritus)、皮膚乾燥 (xerosis)、甲溝炎 (paronychia) 等常見副作用。嚴重的皮膚副作用會導致降低劑量甚至終止給藥。 目前研究指出,表皮的 EGFR 受到抑制之後,會引發表皮生長抑制、分化異常、皮膚角質層常出現異常反應、角質細胞凋亡、細胞激素與趨化激素分泌,進而造成各種皮膚副作用。因此,照護的重點,在於提供良好的保溼、防曬,抑制膿疱皮疹發生、控制癢感、抑制發炎與預防甲溝炎的出現,提升病人生活品質,達到治療的目的。 |
| 英文摘要 | Skin toxicity is the most common side effect in the treatment of epidermal growth factor receptor (EGFR) inhibitors, the incidence is as high as 60-80%. Acneiform eruption, xerosis, pruritus and paronychia are the most common side effects. Serious skin side effects lead to dose reduction or termination of administration. Currently study demonstrated that epidermal EGFR suppressing will lead to epidermal growth suppression, abnormal differentiation of skin, abnormal reaction of stratum corneum, keratinocyte apoptosis, cytokine and chemokine secretion, and cause a variety of skin side effects. Therefore, the focus of care is to provide a good moisturizer, sunscreen, rash pustular rash occurs suppression, control the itching, suppress inflammation and early prevention of paronychia, improve patient quality of life, to achieve therapeutic purposes. |
本系統中英文摘要資訊取自各篇刊載內容。